Alk-001 (no generic name)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
301Macular dystrophy1

301. Macular dystrophy    [ 41 clinical trials,   47 drugs,   (DrugBank: 12 drugs),   12 drug target genes,   66 drug target pathways]
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 41 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02230228
(ClinicalTrials.gov)
April 201427/8/2014Phase 1 Safety Study of ALK-001 in Healthy VolunteersA Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy VolunteersStargardt Disease;Age-related Macular Degeneration;Other Retinal DystrophiesDrug: ALK-001 (No generic name)Alkeus Pharmaceuticals, Inc.NULLCompleted21 Years70 YearsBoth40Phase 1NULL